Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NO1L
|
||||
| Former ID |
DIB006224
|
||||
| Drug Name |
Pascolizumab
|
||||
| Synonyms |
SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Company |
Novartis
|
||||
| CAS Number |
CAS 331243-22-2
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-4 | Target Info | Modulator | [889443] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| T cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Leishmaniasis | |||||
| Measles | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Inflammatory bowel disease (IBD) | |||||
| Allograft rejection | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| TSLP Signaling Pathway | |||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | Notch signaling pathway | ||||
| IL4-mediated signaling events | |||||
| CD40/CD40L signaling | |||||
| IL12-mediated signaling events | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Glucocorticoid receptor regulatory network | |||||
| AP-1 transcription factor network | |||||
| IL2 signaling events mediated by STAT5 | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| References | |||||
| Ref 521497 | ClinicalTrials.gov (NCT00024544) Pilot Study in Patients With Symptomatic Steroid-Naive Asthma. U.S. National Institutes of Health. | ||||
| Ref 542738 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7786). | ||||
| Ref 889377 | ClinicalTrials.gov (NCT01638520) Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.